Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial highlights the urgent unmet clinical need for mechanism-specific therapies for heart failure in patients with diabetes, contextualizing a preclinical study on gene therapy.
This article refers to ‘Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF-1/CXCR4 signalling pathway’ by Z. Dang et al., published in this issue on pages 1568–1581. Heart failure is common in patients with diabetes mellitus1–3 and is associated with particularly poor prognosis. Indeed, clinical outcomes in patients with type 2 diabetes and heart failure are worse than the outcomes in patients with either of the disease processes alone, with a median survival of just 4 years.4 Despite this, treatment of heart failure remains the same, regardless of sex, or whether patients have diabetes and/or other comorbidities. Identification of new mechanisms and targets is of significant importance to tackle this urgent, unmet clinical need. The underlying pathophysiology of heart failure associated with diabetes is multifactorial, with contributions from macrovascular and microvascular dysfunction, direct effects of diabetes on cardiomyocyte biology, as well as secondary to the impact of the disease on renal function and volume overload.5 Indeed, we are still yet to reach complete understanding regarding the breadth of causal factors and mechanisms, and the role each of these plays, in the development of heart failure in the diabetes population (Figure 1).5 As a result, mechanism-specific therapy for the diabetic heart has not been available.
No takes yet. Share an insight, caveat, or question.
Ritchie et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: